(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis

doi:10.3748/wjg.v13.i8.1162

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1982)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

277

HTML

1506

Figures (1-7)

199

Sum=1982

Feb 28, 2007 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (74)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Feb 28, 2007; 13(8): 1162-1169
Published online Feb 28, 2007. doi: 10.3748/wjg.v13.i8.1162

Full Size Figure Download Figure

Figure 3 Suppression of VEGF expression and Stat3 activation in tumor cells and tissues by EGCG. Protein level of VEGF and phosphorylated Stat3 was dose-dependently reduced in tumor cells treated with EGCG and also markedly in EGCG treated tumor tissues. EGCG did not change expression of Stat3 in tumor cells or tumor tissues.

Citation: Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007; 13(8): 1162-1169
URL: https://www.wjgnet.com/1007-9327/full/v13/i8/1162.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i8.1162